Home  /  Latest News  /  ICBCC 2023 Patient Impact Statement

ICBCC 2023 Patient Impact Statement

In 2021, Lymphoma Coalition joined the International COVID-19 Blood Cancer Coalition (ICBCC). The ICBCC comprises representatives from the global patient advocacy and clinical community to address the specific impact of COVID-19 on immunocompromised blood cancer patients (both acute and chronic), like those living with Chronic Lymphocytic Leukaemia (CLL) and other Non Hodgkin lymphomas (NHLs).

In February 2022, the ICBCC released its first Joint Patient Impact Statement, which focused on recommendations for governments and health authorities.

While COVID-19 seems to have become a less severe problem for most populations, some groups like blood cancer patients remain at elevated risk with some profound effects on their lives, and the gradient nature of such risk is not properly acknowledged.

The 2023 revised statement discusses helping patients help themselves to re-engage with the world.

You can read the full 2023 Patient Impact Statement below: